For AbbVie Inc. [ABBV], Atlantic Equities sees a rise to $115; AbbVie Receives Complete Response Letter from FDA

AbbVie Inc. [NYSE: ABBV] plunged by -$0.26 during the normal trading session on Thursday and reaching a high of $99.99 during the day while it closed the day at $98.88. Last week on June 26, Allergan, an AbbVie Company and Molecular Partners made an announcement regarding the issuance of Complete Response Letter from the FDA. The letter has been issued to the Biologics License Application (BLA) for Abicipar pegol.

The FDA issued the letter in response to the application filed for Abicipar pegol which is an investigational DARPin® therapy for neovascular (wet) age-related macular degeneration (nAMD) patients. The CRL mentioned that the rate of intraocular inflammation in the Abicipar pegol 2mg/0.05 mL shows an unfavorable result. The company is looking forward to meeting with the FDA to discuss its statements and then take further steps afterward.

AbbVie Inc. stock has also gained 1.95% of its value over the past 7 days. However, ABBV stock has inclined by 31.61% in the 3 months of the year. Over the past six months meanwhile, it has gained 10.42% and gained 11.68% year-on date.

The market cap for ABBV stock reached $175.82 billion, with 1.48 billion shares outstanding and 1.47 billion shares in the current float. Compared to the average trading volume of 10.46M shares, ABBV reached a trading volume of 6250738 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about AbbVie Inc. [ABBV]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABBV shares is $100.81 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABBV stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Atlantic Equities have made an estimate for AbbVie Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on June 23, 2020. The new note on the price target was released on June 09, 2020, representing the official price target for AbbVie Inc. stock. Previously, the target price had yet another raise to $115, while Argus analysts kept a Buy rating on ABBV stock.

The Average True Range (ATR) for AbbVie Inc. is set at 2.43, with the Price to Sales ratio for ABBV stock in the period of the last 12 months amounting to 5.16. Price to Free Cash Flow for ABBV in the course of the last twelve months was 25.08 with Quick ratio for the last quarter at 3.00.

ABBV stock trade performance evaluation

AbbVie Inc. [ABBV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.95. With this latest performance, ABBV shares gained by 8.79% in over the last four-week period, additionally plugging by 10.42% over the last 6 months – not to mention a rise of 31.91% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABBV stock in for the last two-week period is set at 65.30, with the RSI for the last a single of trading hit 66.19, and the three-weeks RSI is set at 62.88 for AbbVie Inc. [ABBV]. The present Moving Average for the last 50 days of trading for this stock 91.16, while it was recorded at 97.75 for the last single week of trading, and 84.98 for the last 200 days.

AbbVie Inc. [ABBV]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and AbbVie Inc. [ABBV] shares currently have an operating margin of +41.83 and a Gross Margin at +77.14. AbbVie Inc.’s Net Margin is presently recorded at +23.57.

Return on Total Capital for ABBV is now 30.66, given the latest momentum, and Return on Invested Capital for the company is 19.22. Additionally, ABBV Total Debt to Total Capital is recorded at 113.87, with Total Debt to Total Assets ending up at 75.28.

Reflecting on the efficiency of the workforce at the company, AbbVie Inc. [ABBV] managed to generate an average of $261,400 per employee. Receivables Turnover for the company is 5.89 with a Total Asset Turnover recorded at a value of 0.45.AbbVie Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.00 and a Current Ratio set at 3.10.

Earnings per share (EPS) analysis for AbbVie Inc. [ABBV] stock

With the latest financial reports released by the company, AbbVie Inc. posted 2.26/share EPS, while the average EPS was predicted by analysts to be reported at 2.21/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 2.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABBV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AbbVie Inc. go to 10.28%.

AbbVie Inc. [ABBV]: Insider Ownership positions

There are presently around $133,307 million, or 62.90% of ABBV stock, in the hands of institutional investors. The top three institutional holders of ABBV stocks are: VANGUARD GROUP INC with ownership of 147,377,065, which is approximately 2.49% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 119,686,187 shares of the stock with an approximate value of $11.87 billion in ABBV stocks shares; and STATE STREET CORP, currently with $7.94 billion in ABBV stock with ownership of nearly -1.475% of the company’s market capitalization.

Positions in AbbVie Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 1,223 institutional holders increased their position in AbbVie Inc. [NYSE:ABBV] by around 124,606,047 shares. Additionally, 1,116 investors decreased positions by around 104,509,826 shares, while 231 investors held positions by with 1,115,517,146 shares. The mentioned changes placed institutional holdings at 1,344,633,019 shares, according to the latest SEC report filing. ABBV stock had 152 new institutional investments in for a total of 8,334,828 shares, while 153 institutional investors sold positions of 5,354,695 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam